Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Affective Disorders: Eliminate WArning Signs And REstore Functioning: AWARE (AWARE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04701827
Recruitment Status : Recruiting
First Posted : January 8, 2021
Last Update Posted : January 8, 2021
Sponsor:
Information provided by (Responsible Party):
Mental Health Services in the Capital Region, Denmark

Brief Summary:

Affective disorders are associated with impaired functioning and quality of life, as well as comorbid somatic disorders and increased mortality. Despite different medical and psychological treatment options, the prognosis for affective disorder remains largely unchanged. Consequently, the field needs new intervention strategies especially targeting the patient groups having impaired functioning. The core idea of the AWARE project is to focus on improving functioning and quality of life in patients with affective disorders every-day life using a comprehensive 360 degrees intervention.

The trial has a randomized, controlled, parallel-group design. Study participants will be 140 outpatients, male or female age 18-60 with a diagnosis of bipolar disorder or recurrent depressive disorder, in a current state of remission, with an objectively rated impaired functioning. Participant will be randomized to six month AWARE intervention or treatment as usual (TAU).

Assessments encompassing Activities of Daily Living (ADL), neuropsychological testing, mood ratings, physical health and questionnaires on subjective cognitive complaints, psychosocial functioning, quality of life are, sleep quality and satisfaction with psychiatric treatment are carried out at baseline and after the end of treatment.

Discussion: It is hypothesised that the AWARE arm in comparison with standard care will improve observed ability to perform Activities of Daily Living (ADL) and improve Quality of Life.


Condition or disease Intervention/treatment Phase
Mood Disorders Activities of Daily Living Quality of Life Combination Product: AWARE intervention Not Applicable

Detailed Description:

Despite different medical and psychological treatment options, the prognosis for affective disorder remains largely unchanged. Consequently, the field needs new intervention strategies especially targeting the patient groups having impaired functioning.

The core idea in the AWARE project is to focus on improving functioning and quality of life in patients with affective disorders every-day life using a comprehensive 360 degrees intervention. The present AWARE intervention represent an integrated treatment avenue to improve functioning in patients with affective disorders.

The aim of the study is, in a pragmatically Randomised Controlled Trial (RCT), to investigate the effect of a 360 degrees intervention based on the ICF Brief Core Set for BD and unipolar disorder targeting functioning.

The participants will upon inclusion, be randomised to participate in either 6 months AWARE treatment or standard care. The control group will receive standard care consisting of the standard out-patient mental health service routines in The Capital Region of Denmark.

The AWARE intervention targets multiple aspects of the described enhancers of functioning based on on the ICF Brief Core Set, including ADL ability as a part of carrying out daily routines.

The study carried out in a randomized design. The investigators who assess the patients are blinded to whether the patient has participated in the active or passive treatment arm, so the results will be valid. In addition, validated standardized survey methods according to all the outcomes is applied.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Affective Disorders: Eliminate WArning Signs And REstore Functioning: AWARE
Actual Study Start Date : December 15, 2020
Estimated Primary Completion Date : April 1, 2023
Estimated Study Completion Date : December 31, 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Mood Disorders

Arm Intervention/treatment
Experimental: Intervention group
AWARE intervention
Combination Product: AWARE intervention
Comprehensive 360 degrees intervention. The intervention targets multiple aspects of the described enhancers of functioning based on on the ICF Brief Core Set. 1) ADL ability as a part of carrying out daily routines 2) Mood symptoms, medication and side effects 3) Social, relatives and network 4) Physical health, including BMI, biomarkers and exercise5) Cognition, circadian rhythm measured as sleep quality, and coping (stress reduction).

No Intervention: Control group
Treatment as usual (consisting of the standard out-patient mental health service routines in The Capital Region of Denmark)



Primary Outcome Measures :
  1. ADL ability [ Time Frame: 6 month ]
    Assessment of Motor and Process Skills (AMPS) is a standardized observation-based assessment providing measures of the quality of ADL task performance.


Secondary Outcome Measures :
  1. Patient quality of Life [ Time Frame: 6 month ]
    PSS (Cohen's Perceived Stress Scale) and WHOQoL (World Health Organization, Quality of life)

  2. Daily functioning [ Time Frame: 6 month ]
    FAST (Functioning Assessment Short Test) and WHODAS (WHO Disability Assessment Schedule 2.0)


Other Outcome Measures:
  1. Cognitive scores using a composite score from baseline to endpoint and physical health [ Time Frame: 6 month ]
    SCIP, DART and Trailmaiking



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of bipolar disorder or recurrent depressive disorder by ICD-10 diagnostic criteria (confirmed with a diagnostic interview), in a current state of remission (defined as HDRS-17 and YMRS scores of ≤ 7)
  • At inclusion participants must have objectively rated impaired functioning defined as a score ≥ 11 according to the Functioning Assessment Short Test (FAST).
  • Participants must be able to participate in 2/3 of the planned visits.

Exclusion Criteria:

  • Severe somatic disorder interfering with daily living
  • Ongoing alcohol or substance abuse
  • Dementia or inability to cooperate with the study, including inability to speak and read Danish.
  • ECT treatment within last 3 month

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04701827


Contacts
Layout table for location contacts
Contact: Rasmus EV Schwarz, MD + 45 21 42 51 75 rasmus.einar.vagn.schwarz@regionh.dk
Contact: Maj Vinberg, Prof, MD, DMSc + 45 38 64 32 27 maj.vinberg@regionh.dk

Locations
Layout table for location information
Denmark
Psychiatric Centre North Zealand, Copenhagen University Hospital Recruiting
Hillerød, Denmark, 3400
Contact: Bettina Boel    +45 38 64 30 44    bettina.boel@regionh.dk   
Sponsors and Collaborators
Mental Health Services in the Capital Region, Denmark
Investigators
Layout table for investigator information
Study Director: Maj Vinberg, Prof, MD, DMSc Psychiatric Centre North Zealand, Copenhagen University Hospital
Layout table for additonal information
Responsible Party: Mental Health Services in the Capital Region, Denmark
ClinicalTrials.gov Identifier: NCT04701827    
Other Study ID Numbers: H-20029748
First Posted: January 8, 2021    Key Record Dates
Last Update Posted: January 8, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Time Frame: No current time frame
Access Criteria: Reasonable request

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Mental Health Services in the Capital Region, Denmark:
Bipolar disorder
Mental disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Mood Disorders
Pathologic Processes
Mental Disorders